Eclipse has a unique and promising cancer stem cell therapeutic antibody program supported by a world-class team of scientists and management.
San Diego , California (PRWEB) February 01, 2012
Eclipse Therapeutics, Inc. (“Eclipse”), a biotechnology company dedicated to the discovery and development of novel therapeutics that target cancer stem cells, announced today the appointments of Hans Clevers, M.D., Ph.D., and Thomas Kipps, M.D., Ph.D., to its Scientific Advisory Board.
“As we advance our lead therapeutic antibody program targeting cancer stem cells in colon and other cancers into the clinic, Dr. Clevers and Dr. Kipps will provide Eclipse with invaluable scientific and clinical perspectives,” said Peter Chu, Ph.D., Eclipse Therapeutics’ President and co-founder. He added, "Dr. Clevers is the world’s foremost expert on colon stem cell biology and will play an integral role in guiding the development of Eclipse’s unique drug candidate targeting a high value, validated novel colon cancer stem cell receptor. Dr. Kipps is a world renowned clinical oncologist whose deep experience in translational bench-to-bedside medicine in cancer will help Eclipse advance its drug programs into the clinic.”
Hans Clevers, M.D., Ph.D., is Director of the Hubrecht Laboratory and Netherlands Institute of Developmental Biology in Utrecht, Netherlands. Over the past twenty years, Dr. Clevers’ research has been instrumental in revealing the process by which normal intestinal stem cells transform into cancer stem cells and ultimately colon cancer. He is one of the leading experts on the Wnt-ß-Catenin signaling pathway. Dr. Clevers’ work has been published in numerous leading journals, including 31 papers alone in Cell, Science and Nature. Dr. Clevers performed his post-doctoral training at the Harvard-affiliated Dana-Farber Cancer Institute. He has been a member of the Royal Dutch Academy of Sciences since 2000 and is the recipient of many awards, including the prestigious Spinoza Award in 2001, the Louis Jeantet Prize in 2004, the Memorial Sloan-Kettering Katharine Berkan Judd Award in 2005, the Rabbi Shai Shacknai Prize in 2006 and the Kolff Prize in 2011. Dr. Clevers also has founded multiple biotechnology companies, including Semaia Pharmaceuticals which was acquired by Hybrigenics SA. He currently serves on the advisory boards of venture capital firms Life Sciences Partners B.V. and Aglaia Biomedical Ventures B.V.
“I am honored to be a founding member of Eclipse’s Scientific Advisory Board. Eclipse has a unique and promising cancer stem cell therapeutic antibody program supported by a world-class team of scientists and management. They have already established themselves as a leading cancer stem cell company, and I look forward to working with them to develop drugs that significantly improve the lives of patients with cancer,” said Dr. Clevers.
Thomas Kipps, M.D., Ph.D. is the Evelyn & Edwin Tasch Chair in Cancer Research and Interim Director of the Moores Cancer Center at the University of California, San Diego. Dr. Kipps received his M.D. and Ph.D. degrees with magna cum laude honors from Harvard University and performed his residency and fellowship training at Stanford University. He has extensive experience in drug discovery and development, taking multiple products from conception to clinical trials and commercialization. In addition to conducting translational bench research, Dr. Kipps also has led numerous investigator-initiated or industry-sponsored registration clinical studies in cancer, directs the multi-institutional, NIH-sponsored CLL research consortium, and is a two-time awardee of the NIH MERIT Award. He also leads a cancer stem cell antibody program funded by a $20M grant from the California Institute for Regenerative Medicine. Dr. Kipps has 20 years’ experience in combining research and clinical care responsibilities, and has authored nearly 300 publications spanning the fields of basic, translational and clinical oncology.
“I am pleased and excited to join such a dynamic and talented scientific team and believe in the potential of Eclipse Therapeutics’s technology targeting cancer stem cells to develop much needed novel therapies for cancer patients,” said Dr. Kipps.
About Eclipse Therapeutics, Inc.
Eclipse Therapeutics, Inc. (“Eclipse”) is a private biotechnology company dedicated to the discovery and development of therapeutics that target cancer stem cells and other forms of innovative cancer treatment. Cancer stem cells are a subset of cells within a tumor thought to play a critical role in tumor initiation, recurrence and metastasis. They are also implicated in resistance to current standard of care cancer treatments. Eclipse is leveraging its deep expertise in cancer stem cell biology and therapeutic antibodies to develop novel therapeutics that address unmet needs in cancer patient care. For more information, please visit http://www.eclipsetherapeutics.com.